Therapeutic Approach

Category: Uncategorized

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update   LOS ANGELES (August 14, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial […]

Leave Your Comments »

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES (August 8, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products […]

Leave Your Comments »

Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings

Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28 LOS ANGELES(July 31, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to […]

Leave Your Comments »

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES (July 11, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that it […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES (July 2, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed their final visit in the Company’s first […]

Leave Your Comments »

Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

LOS ANGELES (June 20, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first Food and Drug Administration (FDA)-approved […]

Leave Your Comments »

Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer

Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES (May 30, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

LOS ANGELES (May, 14 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (“LI”), today reported […]

Leave Your Comments »

Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout on Target for early Q4 2019 LOS ANGELES (May 7, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split

Los Angeles, California, March 1, 2018 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on establishing the first FDA-approved treatment for lactose intolerance, today announced that its Board of Directors (the “Board”) […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD